Cetuximab in Combination With Cisplatin or Carboplatin and 5-fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

Cetuximab in Combination With Cisplatin or Carboplatin and 5-fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Fluorouracil
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EXTREME
  • Sponsors Merck KGaA
  • Most Recent Events

    • 03 Jun 2014 Results at 5-year folllow-up presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 29 Sep 2011 Actual end date changed from Jul 2007 to Jul 2011 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Quality of life results published in Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top